By Lisa Kerner
Erie, Pa., March 2 - ARCA Discovery, Inc. said it completed a $15 million round of series A venture capital financing.
The financing was led by Atlas Venture. Boulder Ventures and Pequot Capital Management also participated.
"This round of financing allows us to complete the filing of a New Drug Application for bucindolol, the first genetically targeted cardiovascular drug," ARCA founder and chief executive officer Michael R. Bristow said in a company news release.
Jean Francois Formela, a senior partner with Atlas, will join ARCA's board of directors in connection with the financing.
Denver-based ARCA develops genetically targeted therapies for heart failure and other cardiovascular diseases.
| Issuer: | ARCA Discovery, Inc.
|
| Issue: | Venture capital
|
| Amount: | $15 million
|
| Investors: | Atlas Venture (lead), Boulder Ventures, Pequot Capital Management
|
| Announcement date: | March 2
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
